BioWorld Asia

March 19, 2003

For $55M, OSI Gets Novantrone U.S. Cancer Rights From Serono

Serono SA signed a licensing agreement with OSI Pharmaceuticals Inc., granting OSI exclusive rights to market and promote Novantrone in the U.S. in its approved oncology indications. (BioWorld International) Read More

OncoGenome Sciences Raises EUR14M For Cancer Diagnostics

New Drugs Could Flow From Bacterial Gene Cluster Variants

UroGene Second Round: EUR12M For Itself, Subsidiary Chrysalon

Riding Smallpox Contracts, Acambis Reports 2002 Profit

EU Worries More Biotechnology Companies Could Quit Europe

Entomed, Naeja Enter Two-Way Cancer, Infectious Diseases Deal

Potential OGS Buyers, CAT, Celltech, Jockey For Position

CellFactors Seeking £3.5M To Advance, Partner Skeletex

Products, Fundamentals Find Investor Favor In Down Market

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 22, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

Nankai University and Accendatech present new majusculamide D derivatives

BioWorld Science

Scientists from Nankai University Tianjin and Accendatech Technology Co. Ltd. have identified a majusculamide D derivative found to be useful for the treatment of...